ABBV's fourth-quarter earnings and sales beat estimates. Management raises the 2027 forecast for newer immunology drugs to more than $31 billion.
Shorter protective caps on chromosomes called telomeres, a proposed marker of accelerated biological cell aging, may be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback